Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenuePayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Liabilities and Shareholders Equity (2022 - 2025)

Historic Liabilities and Shareholders Equity for Coya Therapeutics (COYA) over the last 4 years, with Q3 2025 value amounting to $32.0 million.

  • Coya Therapeutics' Liabilities and Shareholders Equity fell 987.0% to $32.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $148.2 million, marking a year-over-year decrease of 382.67%. This contributed to the annual value of $44.3 million for FY2024, which is 747.59% up from last year.
  • As of Q3 2025, Coya Therapeutics' Liabilities and Shareholders Equity stood at $32.0 million, which was down 987.0% from $33.5 million recorded in Q2 2025.
  • In the past 5 years, Coya Therapeutics' Liabilities and Shareholders Equity ranged from a high of $44.3 million in Q4 2024 and a low of $8.4 million during Q4 2022
  • For the 4-year period, Coya Therapeutics' Liabilities and Shareholders Equity averaged around $29.5 million, with its median value being $34.5 million (2024).
  • As far as peak fluctuations go, Coya Therapeutics' Liabilities and Shareholders Equity soared by 39147.7% in 2023, and later plummeted by 1624.01% in 2025.
  • Quarter analysis of 4 years shows Coya Therapeutics' Liabilities and Shareholders Equity stood at $8.4 million in 2022, then soared by 391.48% to $41.3 million in 2023, then rose by 7.48% to $44.3 million in 2024, then decreased by 27.75% to $32.0 million in 2025.
  • Its last three reported values are $32.0 million in Q3 2025, $33.5 million for Q2 2025, and $38.4 million during Q1 2025.